TransMedics Group, Inc. (NASDAQ:TMDX) Shares Bought by Vaughan Nelson Investment Management L.P.

Vaughan Nelson Investment Management L.P. grew its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 9.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 361,615 shares of the company's stock after acquiring an additional 32,605 shares during the period. Vaughan Nelson Investment Management L.P. owned about 1.08% of TransMedics Group worth $22,547,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of TMDX. Hager Investment Management Services LLC bought a new position in TransMedics Group in the 4th quarter worth $33,000. Sachetta LLC bought a new position in TransMedics Group in the 4th quarter worth $40,000. Quarry LP boosted its holdings in TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company's stock worth $58,000 after buying an additional 312 shares during the period. National Bank of Canada FI boosted its holdings in TransMedics Group by 174.7% in the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company's stock worth $65,000 after buying an additional 262 shares during the period. Finally, Farther Finance Advisors LLC boosted its holdings in TransMedics Group by 187.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company's stock worth $76,000 after buying an additional 316 shares during the period. Institutional investors own 99.67% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. TD Cowen decreased their price target on shares of TransMedics Group from $175.00 to $120.00 and set a "buy" rating on the stock in a research note on Monday, November 18th. Robert W. Baird decreased their price target on shares of TransMedics Group from $150.00 to $120.00 and set an "outperform" rating on the stock in a research note on Wednesday, December 11th. Canaccord Genuity Group decreased their price target on shares of TransMedics Group from $109.00 to $104.00 and set a "buy" rating on the stock in a research note on Wednesday, November 20th. Piper Sandler decreased their price target on shares of TransMedics Group from $110.00 to $90.00 and set an "overweight" rating on the stock in a research note on Wednesday, December 11th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research note on Wednesday, February 5th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $122.70.

Insiders Place Their Bets

In other news, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the transaction, the insider now directly owns 20,843 shares in the company, valued at approximately $1,800,835.20. This trade represents a 4.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 7.00% of the company's stock.

TransMedics Group Trading Up 2.4 %

TMDX stock traded up $1.70 during mid-day trading on Thursday, reaching $71.22. The company had a trading volume of 1,208,318 shares, compared to its average volume of 2,341,104. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company has a market capitalization of $2.39 billion, a PE ratio of 75.77 and a beta of 2.12. The firm has a 50 day moving average of $65.69 and a 200 day moving average of $107.72. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.